Patent 7432248 was granted and assigned to Genelabs Technologies on October, 2008 by the United States Patent and Trademark Office.
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: